Panelists discuss how the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) encompasses multiple therapeutic options including novel hormonal agents, ...

Experts discuss the standard of care and the use of intravesical chemotherapy in the treatment of non–muscle-invasive bladder cancer (NMIBC).

Panelists discuss how radiopharmaceuticals like lutetium-177 prostate-specific membrane antigen (PSMA) may be preferred over systemic therapy in patients with prostate cancer who have high PSMA ...

“In the setting of widespread metastatic progression or failure, we typically prefer more systemic therapy with metastasis-directed therapy for symptomatic sites,” says Kate H. Gessner, MD, PhD. In ...

"I'm always trying new things. I feel like, once you decide that this is the way you have to do it and stick with that forever, that's when you immediately become irrelevant," says Amy E. Krambeck, MD ...

"I'm always trying new things. I feel like, once you decide that this is the way you have to do it and stick with that forever, that's when you immediately become irrelevant," says Amy E. Krambeck, MD ...

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.

The FDA has accepted the BLA for 89Zr-DFO-girentuximab, granting it priority review for ccRCC imaging. The ZIRCON trial showed high sensitivity (85.5%) and specificity (87%) for the agent in detecting ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23 ...

“Having a broader understanding of why someone might be experiencing the disease process or symptoms that they're coming in with is really meaningful and helpful, both to patients and to physicians,” ...

The redePHine trial is expected to launch in the first half of 2025.